https://www.selleckchem.com/products/apx2009.html 8 (95% CI 0.27-1.31) p  less then  0.001]; CARE Measure [1.0 (95% CI 0.45-1.55) p  less then  0.001], POSITIVE OUTCOMES [0.7 (95% CI 0.17-1.23) p  less then  0.001]. Post-trial interviews revealed general acceptability of the intervention. The results confirm the feasibility and justify a definitive cRCT of the enhanced care intervention to improve person-centred outcomes for PLWH.Trial registration number ISRCTN13630241.RATIONALE Individuals eligible for lung cancer screening (LCS) by low-dose computed tomography (LDCT) are also at risk of Chronic Obstructive Pulmonary Disease (COPD) due to age and smoking exposure. Whether the LCS episode is useful for early detection of COPD is not well established. OBJECTIVES To explore associations between symptoms, comorbidities, spirometry and emphysema in participants enrolled in the Lung Screen Uptake Trial (LSUT). METHODS This cross-sectional study was a pre-specified analysis nested within LSUT, which was a randomized study testing the impact of differing invitation materials on attendance of 60-75 year-old smokers and ex-smokers to a 'lung health check' between November 2015 and July 2017. Participants with a smoking history ≥30 pack-years and quit ≤15 years ago, or meeting a lung cancer risk of ≥1.51% via the Prostate Lung Colorectal Ovarian (PLCOm2012) model or ≥2.5% via the Liverpool Lung Project (LLP) model, were offered LDCT. COPD was defined and classified according to the GOR GOLD 1&2 1.57, CI 1.14-2.17; aOR GOLD 3&4 4.6, CI 2.17-9.77); than emphysema (aOR mild 1.12, CI 0.81-1.55; aOR moderate 1.33, CI 0.85-2.09; aOR severe 4.00, CI 1.57-10.2). CONCLUSIONS There is high burden of 'undiagnosed COPD' and emphysema in LCS participants. Adding spirometry findings to the LDCT enhances identification of individuals with COPD. Clinical trial registered with ClinicalTrials.gov (NCT02558101).BACKGROUND The paucity of available hearts for transplantation means that more pati